A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Inclusion Criteria

• •Patients must have a diagnosis of one of the following:
• •* relapsed or refractory AML or ALL that has failed to respond to standard therapy, has progressed despite standard therapy
• •* relapsed or refractory Myelodysplastic Syndromes
• •* previously untreated AML or Myelodysplastic Syndromes in patients \> 60 years of age who refused or are not candidates for induction chemotherapy
• •Patients with relapsed or refractory CML that has failed to respond to Imatinib therapy or standard therapy, has progressed despite standard therapy, or for which no standard therapy exists
• •ECOG performance status of 0, 1, or 2
• •Age ≥ 18 years
• •Patients or their legal representative must be able to read, understand, and sign a written informed consent (approved by the IRB/EC) prior to study entry